Fonar (FONR) Stock Price, News & Analysis

Company Overview

Fonar Corporation (NASDAQ: FONR) is a medical technology company specializing in the development, manufacture and service of magnetic resonance imaging (MRI) systems. Founded in 1978 and headquartered in Melville, New York, the company offers a range of MRI solutions designed to provide high-resolution diagnostic imaging in both clinical and research settings. Fonar’s product line includes its signature Upright™ MRI scanners, which enable patients to be scanned in weight-bearing positions, as well as open and semi-open MRI units tailored to various clinical applications.

The company’s core activities encompass research and development, system production, sales, installation and ongoing maintenance of MRI equipment. Fonar invests in proprietary technologies aimed at enhancing image quality, reducing scan times and improving patient comfort. Its service division delivers nationwide and international support, including preventive maintenance, on-site repairs and remote technical assistance. Through distributor partnerships and direct sales efforts, Fonar has installed systems in hospitals, imaging centers and research institutions around the globe.

Fonar’s origins are closely tied to the pioneering work of its late founder, Dr. Raymond V. Damadian, who performed the world’s first full-body MRI scan and founded the company to commercialize the technology. Under Dr. Damadian’s leadership, Fonar received the first U.S. Food and Drug Administration clearance for a commercial MRI scanner in 1980, establishing a foundation for the widespread adoption of MRI as a noninvasive diagnostic tool. Over the decades, Fonar has continued to innovate, securing patents for its upright imaging capabilities and developing enhancements that address both spinal and musculoskeletal applications.

Today, Fonar is led by President and Chief Executive Officer Stephen R. Dwoskin, whose background in medical device finance and operations underpins the company’s growth strategies. Alongside a seasoned management team, Dwoskin focuses on expanding Fonar’s global footprint, advancing technology development and strengthening customer support networks. With its combination of specialized upright MRI platforms and comprehensive service offerings, Fonar remains a distinctive player in the medical imaging industry.

Key Stats

• Today's Range: $15.33 to $15.79
• 50-Day Range: $12.17 to $15.80
• 52-Week Range: $12.00 to $18.68
• Volume: 20,185 shs
• Average Volume: 17,372 shs
• Market Capitalization: $95.85 million
• P/E Ratio: 12.37
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Fonar Stock Analysis - MarketRank™

Fonar scored higher than 25% of companies evaluated by MarketBeat, and ranked 806th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Fonar.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Fonar is 12.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.73.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fonar is 12.53, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.42.

Price to Book Value per Share Ratio

Fonar has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.67% of the float of Fonar has been sold short.

Short Interest Ratio / Days to Cover

Fonar has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Fonar has recently increased by 52.24%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fonar does not currently pay a dividend.

Dividend Growth

Fonar does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.67% of the float of Fonar has been sold short.

Short Interest Ratio / Days to Cover

Fonar has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Fonar has recently increased by 52.24%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.25

News Sentiment

Fonar has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Fonar this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Fonar insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.55% of the stock of Fonar is held by insiders.

Percentage Held by Institutions

50.64% of the stock of Fonar is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

FONR Stock Analysis - Frequently Asked Questions

How have FONR shares performed this year?

Fonar's stock was trading at $15.14 on January 1st, 2025. Since then, FONR shares have increased by 3.5% and is now trading at $15.6650.

How were Fonar's earnings last quarter?

Fonar Corporation (NASDAQ:FONR) released its quarterly earnings results on Thursday, May, 15th. The medical equipment provider reported $0.37 earnings per share (EPS) for the quarter. Fonar had a trailing twelve-month return on equity of 5.31% and a net margin of 8.19%.

How do I buy shares of Fonar?

Shares of FONR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Fonar own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Fonar investors own include Waste Connections (WCN), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), American Water Works (AWK), DiamondRock Hospitality (DRH), AU Optronics (AUOTY) and Voyager Therapeutics (VYGR).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/07/2025
• Next Earnings (Estimated): 9/25/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:FONR
• CIK: 355019
• Web: www.fonar.com
• Phone: (631) 694-2929
• Fax: 631-753-5150
• Employees: 480
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $1.25
• Trailing P/E Ratio: 12.64
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $10.57 million
• Net Margins: 8.19%
• Pretax Margin: 13.85%
• Return on Equity: 5.31%
• Return on Assets: 3.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.05
• Quick Ratio: 9.86

Sales & Book Value

• Annual Sales: $102.88 million
• Price / Sales: 0.95
• Cash Flow: $3.12 per share
• Price / Cash Flow: 5.07
• Book Value: $24.78 per share
• Price / Book: 0.64

Miscellaneous

• Outstanding Shares: 6,200,000
• Free Float: 6,107,000
• Market Cap: $97.98 million
• Optionable: Not Optionable
• Beta: 1.00